A new article by Dr. Howard Scher of Memorial Sloan-Kettering Cancer Center on the OncologySTAT web site discusses recent developments in the application of levels of circulating tumor cells (CTCs) in clinical practice and in the assessment of outcomes in clinical trials. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: circulating tumor cells, CTCs | Leave a comment »
To date there has only been one test available for assay of levels of circulating tumor cells (CTCs) in men with prostate cancer: the CellSearch test made by Veridex. This test is widely recognized to come with a variety of challenges, and the potential of CTCs in assessing risk for progression of prostate cancer (and other cancers) has therefore been limited. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: circulating tumor cells, circulating tumor stem cells, CTC, CTSC, outcome, prognosis | Leave a comment »
According to an Associated Press story that came out this morning, Johnson & Johnson and “Boston scientists” are working together on “A blood test so sensitive that it can spot a single cancer cell lurking among a billion healthy ones.” … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: blood, circulating tumor cells, CTCs, HB-Chip | 10 Comments »
Circulating tumor cell (CTC) levels have clearly been shown to have relevance to the prognosis of men with metastatic, castration-resistant prostate cancer, but we still know little about their potential importance in men with early stage disease. … READ MORE …
Filed under: Management, Risk | Tagged: circulating tumor cells, CTC, radical prostatectomy | 11 Comments »
Our third report today covers such topics as:
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: biopsy, blood, circulating tumor cells, CTCs, Diagnosis, DNA, functional, IMRT, MRI, New Zealand, nomogram, radical prostatectomy, risk, technique, treatment planning | Leave a comment »
For the engineers, the scientists, and other technically minded readers, there are a number of very “dense” scientific news reports today. … READ MORE …
Filed under: Diagnosis, Management, Treatment | Tagged: circulating tumor cells, CTC, MRI, OCT, optical coherence tomography, segmentation | 2 Comments »
Intermediate or surrogate endpoints for survival can shorten timelines for drug approval. A paper just published on line in Lancet Oncology aimed to assess the value of circulating tumor cell (CTC) counts as a prognostic factor for survival. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: circulating tumor cells, clinical trials, CTC, surrogate endpoint | Leave a comment »
There are a number of additional reports in today’s news (above and beyond the reports on risks associated with disseminated tumor cells and a new review of PSA and PCA3 testing as aids to diagnosis): … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: circulating tumor cells, CTC, focal therapy, lycopene, silibinin, unilateral | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 